CORRECTED: Novartis Knocks Colombia Over Leukemia Drug Price Control

Law360, New York (December 1, 2016, 7:22 PM EST) -- Swiss pharmaceutical giant Novartis has threatened to file an investor-state claim against Colombia over the country's decision to require a price control on Novartis' leukemia drug Glivec, a spokesman for the company confirmed on Thursday. 

The spokesman told Law360 that the company had filed its notice of dispute over certain intellectual property rights under a bilateral investment treaty between the South American nation and Switzerlan in April, several months before Colombia's Ministry of Health issued a decision in June to enforce a declaration of public interest requiring...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.